<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-09000470</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2009-07-15</date_registration>
      <primary_sponsor>People's hospital of Peking University</primary_sponsor>
      <public_title>Randomized control trial of the conditioning BUCy regimen with fludarabincin instead of cyclophosphomide in allogeneic hematopoietic stem cell transplantation from identical siblings</public_title>
      <acronym />
      <scientific_title>Randomized control trial of the conditioning BUCy regimen with fludarabincin instead of cyclophosphomide in allogeneic hematopoietic stem cell transplantation from identical siblings</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2009-01-01</date_enrolment>
      <type_enrolment />
      <target_size>Group B:100;Group A:100;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=9064</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>Other</phase>
      <hc_freetext>Hematological malignancies</hc_freetext>
      <i_freetext>Group B:cyclophosphomide, 1.8g/m2/d*2d, intravenouly;Group A:fludarubincin, 30mg/m2/dx3d, intravenously  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Daihong Liu</firstname>
        <middlename />
        <lastname />
        <address>No.11, South Xizhimen Street, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 13681171597</telephone>
        <email>daihongk1@yahoo.com.cn</email>
        <affiliation>People's hospital of Peking University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiaojun Huang</firstname>
        <middlename />
        <lastname />
        <address>No.11, South Xizhimen Street, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 010 88326006</telephone>
        <email>xjhrm@medmail.com.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Male and female aged 18 to 55 years old;
2. Hematological malignancies indicating for allogeneic transplantation, with identical sibling as donor, with indication for the previous modified BUCY conditioning;
3. Signed informed consent.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>55</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients whose organ function can not tolerate the myeloablative transplantation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Transplantation related mortality;Rate of survival and relaps;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Incidence of engraftment, opportunistic infection,;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-funding</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>